302 related articles for article (PubMed ID: 11116277)
1. Pharmacological treatment of the ion transport defect in cystic fibrosis.
Roomans GM
Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
Roomans GM
Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
[TBL] [Abstract][Full Text] [Related]
3. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.
Andersson C; Roomans GM
Eur Respir J; 2000 May; 15(5):937-41. PubMed ID: 10853862
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
5. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells.
Suaud L; Miller K; Alvey L; Yan W; Robay A; Kebler C; Kreindler JL; Guttentag S; Hubbard MJ; Rubenstein RC
J Biol Chem; 2011 Jun; 286(24):21239-53. PubMed ID: 21525008
[TBL] [Abstract][Full Text] [Related]
6. New horizons in the treatment of cystic fibrosis.
Cuthbert AW
Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
Srivastava M; Eidelman O; Pollard HB
Mol Med; 1999 Nov; 5(11):753-67. PubMed ID: 10656877
[TBL] [Abstract][Full Text] [Related]
8. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis.
Grubb BR; Gabriel SE; Mengos A; Gentzsch M; Randell SH; Van Heeckeren AM; Knowles MR; Drumm ML; Riordan JR; Boucher RC
Am J Respir Cell Mol Biol; 2006 Mar; 34(3):355-63. PubMed ID: 16284361
[TBL] [Abstract][Full Text] [Related]
9. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.
Guay-Broder C; Jacobson KA; Barnoy S; Cabantchik ZI; Guggino WB; Zeitlin PL; Turner RJ; Vergara L; Eidelman O; Pollard HB
Biochemistry; 1995 Jul; 34(28):9079-87. PubMed ID: 7542476
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
Rubenstein RC; Zeitlin PL
Am J Respir Crit Care Med; 1998 Feb; 157(2):484-90. PubMed ID: 9476862
[TBL] [Abstract][Full Text] [Related]
11. No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine.
Kunzelmann K; Briel M; Schreiber R; Ricken S; Nitschke R; Greger R
Cell Physiol Biochem; 1998; 8(4):185-93. PubMed ID: 9694345
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia.
Devor DC; Bridges RJ; Pilewski JM
Am J Physiol Cell Physiol; 2000 Aug; 279(2):C461-79. PubMed ID: 10913013
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
Rubenstein RC; Egan ME; Zeitlin PL
J Clin Invest; 1997 Nov; 100(10):2457-65. PubMed ID: 9366560
[TBL] [Abstract][Full Text] [Related]
14. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
Lim M; McKenzie K; Floyd AD; Kwon E; Zeitlin PL
Am J Respir Cell Mol Biol; 2004 Sep; 31(3):351-7. PubMed ID: 15191910
[TBL] [Abstract][Full Text] [Related]
15. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB
Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888
[TBL] [Abstract][Full Text] [Related]
16. Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR).
Caohuy H; Yang Q; Eudy Y; Ha TA; Xu AE; Glover M; Frizzell RA; Jozwik C; Pollard HB
J Biol Chem; 2014 Dec; 289(52):35953-68. PubMed ID: 25384981
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of the ion transport defect in cystic fibrosis.
Kunzelmann K; Mall M
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):857-67. PubMed ID: 11703384
[TBL] [Abstract][Full Text] [Related]
19. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells.
Dragomir A; Björstad J; Hjelte L; Roomans GM
Biochem Biophys Res Commun; 2004 Sep; 322(2):447-51. PubMed ID: 15325250
[TBL] [Abstract][Full Text] [Related]
20. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator.
Poulsen JH; Fischer H; Illek B; Machen TE
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5340-4. PubMed ID: 7515498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
